The year started well for CZM with revenue growing 9% (at CER) in Q1, led by robust growth momentum in Ophthalmology and Microsurgery. Geographically, APAC and EMEA reported double-digit growth, while the Americas traded in the red. While operating profit surged 23.1%, due to temporarily reduced R&D expenses, higher financial and tax expenses meant that the EPS was flat yoy. Given CZM’s robust product portfolio, the company remains on track to meet its revenue and profitability targ
12 Feb 2019
Good start to the year

